The company said that it received orders for 135 of its NovaSeq sequencing instrument in the first quarter 2017.
The firm will scale up manufacturing of its nanopore sensor, expand its executive team, and push development of its sequencing and genome mapping applications.
The firm has received approval for two unspecified clinical tests, with a permit under the molecular genetic testing category.
Using point mutation and structural variant patterns in 133 ovarian cancer cases, researchers identified seven clusters to classify the disease and predict patient outcomes.
The partners will work together to develop a breast cancer recurrence risk score using the company's technology.
Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.
An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.
At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.
In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.
This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.
This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.
This webinar will provide an overview of an RNA-seq protocol that has been optimized to study small RNA species such as microRNAs.
This webinar will discuss a target enrichment workflow for high-confidence detection of variants.